Artificial wombs are recreating pregnancy outside the body, keeping premature life developing in controlled environments.
Synthetic embryo models, such as blastoids and gastruloids, which replicate key stages in mammalian embryogenesis in vitro, are slowly gaining traction as viable means of ex-vivo development. These stem cell-derived “embryos” replicate stages in blastocyst and early post-implantation development without using any embryo tissue.
For example, synthetic blastoids develop a blastocoel cavity and the three main cell types within one week, just like natural blastocysts. Similarly, 3D stem cell aggregates, termed gastruloids, develop symmetry-breaking and germ layer formation to produce body axis and organ primordia structures . These synthetic “embryos” develop under tightly controlled conditions. For example, stem cells aggregate spontaneously in microwells , where aggregate size and shape are controlled. Alternatively, stem cells can be plated in micropatterned substrates, where cell positioning is controlled. In addition, microfluidic chips can be used to deliver specific gradients of morphogens and nutrients to stem cell aggregates, thus controlling symmetry-breaking. Such engineered embryo models offer an unprecedented platform to study implantation, morphogenesis, and congenital defects without using human embryos.To complement these “petri-dish embryos,” engineers are developing “artificial womb systems” that will prolong gestation periods outside of the body. These systems will mimic the conditions of the womb, including a sterile, temperature-controlled “fluid bath” of “artificial amniotic fluid” surrounding the fetus, and an “artificial placenta/oxygenator” that will supply oxygen through the umbilical cord. A standard “artificial womb system” includes three parts: a “pumpless arteriovenous circuit” in which the fetal heart itself circulates blood through a “low resistance oxygenator”; a “closed fluid environment” such as a “Biobag” or “bag”; and “umbilical access” that mimics the normal flow of blood in the umbilical arteries and vein.One landmark study by the Children’s Hospital of Philadelphia has shown that an extra-uterine system can support extremely preterm lambs for weeks. The researchers at the CHOP designed a single-use “Biobag”, which consists of a “transparent polyethylene pouch filled with a synthetic amniotic fluid. Asreported: “The Biobag consists of polyethylene film that is translucent, sonolucent and flexible to permit monitoring… After cannulation, the Biobag is sealed… The development of the Biobag essentially solved the problem of gross fluid contamination, and has eliminated pneumonia on lung pathology.” Eight fetal lambs were supported in this system. Five lambs ran for 25–28 days, and three lambs for 20–28 days. Importantly, these durations were limited by animal study protocols, not technical failure: “The longest runs were terminated at 28 days due to protocol limitations rather than any instability,” the authors note, “suggesting that support… could be maintained beyond 4 weeks”. Throughout the Biobag runs, fetal physiology remained normal: circuit blood flow stayed equivalent to placental norms , gas exchange met metabolic needs, andWith nutrition and hormone support, the lambs developed as they would in utero. “Lambs on support maintain stable haemodynamics, have normal blood gas and oxygenation parameters,” the authors report, and with “appropriate nutritional support… demonstrate normal somatic growth, lung maturation, and brain growth and myelination.” In one notable case, a lamb was sustained for 288 hours and then weaned to breathe on its own, with long-term survival thereafter. These results surpassed all prior attempts at extracorporeal fetal support. As theputs it, the Biobag “closely reproduces the environment of the womb,” allowing the fetus to grow as if it had never left its mother. The major technical innovations in this case include the following: the pumpless arteriovenous circuit, in which the fetal heart pumps blood through a low-resistance hollow-fiber lung; the closed fluid loop, in which there is minimal risk of contamination; and the refined umbilical cannulation, in which the tip of the venous cannula is advanced into the abdominal wall to prevent spasm. In addition, the team refined the oxygenation process by adding nitrogen to the sweep gas in order to maintain the fetal PaO2 levels in the physiologic range and prevent toxicity. These engineering innovations, implemented in a mobile support platform, represent the first working prototype of an artificial uterus for mammalian gestation.Several groups worldwide have followed this lead. At the University of Michigan’s C.S. Mott Children’s Hospital, researchers, led by Dr. George Mychaliska, in Dr. Robert Bartlett’s lab on ECMO, developed an “artificial placenta” by adapting the ECMO circuit. Their system consisted of submerging pre-term lambs in artificial amniotic fluid, where a pumpless oxygenator, supplied by a sweep gas, mimicked placental perfusion. Preliminary data show this approach can bridge extremely premature lambs for up to 16 days. Importantly, echocardiographic and histologic analyses indicate normal fetal circulation and preserved organ development . “These findings are very promising,” the team reported, “suggesting that our technology is protective of the lungs and brain development in premature animals.” Based on these successes, they “anticipate a clinical trial within five years”. Dr. Mychaliska emphasizes that an artificial placenta could be “a complete paradigm shift in treating prematurity,” re-creating the intrauterine environment so that critical organs can continue to mature outside the womb. Engineering groups in Japan and Europe have also developed their own oxygenators. A pumpless oxygenator developed by Miura et al. utilized a parallelized dual circuit oxygenator to significantly reduce resistance. In preterm lambs, survival time increased from ~18 hours to ~60 hours. In vitro studies conducted at University of Pittsburgh created a hollow-fiber oxygenator with a size suitable for the blood flow of the human fetus. Their geometry was calculated using computational fluid dynamics and predicted that the device would be capable of removing 12.2 mL CO2/min with a blood flow of 165 mL/min and resistance of<71 mmHg min L^–1. In vitro tests confirmed the predictions made by the computational fluid dynamics model. In fact, the results of the in vitro tests showed that the device removed ~4% more than the predicted value. Moreover, no damage to the red blood cells was observed with full flow. All of the above developments using silicon microfabricated membranes and hollow fiber bundles are indicative of the intense engineering efforts being made in the development of the artificial placenta device with optimal gas exchange per unit volume and biocompatibility with minimal clotting and hemolysis.The uterine environment is a soft environment with low shear rates. Artificial devices must provide a uniform flow and mixing of the amniotic fluid without the presence of disturbing flows or stagnant areas. Laminar flow conditions and gentle perfusion pumps are used; in addition, CFD simulations verify the absence of stagnant areas or high shear rates that could be detrimental to the tissues. An important aspect is the achievement of physiological pressure levels since the artificial placenta has to present a low resistance, a few tens of mmHg, similar to the natural placenta . Parallelizing the oxygenator channels or membranes, as in the case of the work by Miura et al., may cut the pressure in half and allow a greater flow at a given ventricular pressure.Engineers must balance oxygen delivery precisely. In utero, fetal PaO₂ is low , and excessive O₂ can suppress erythropoiesis. The Penn team thus lowered the O₂ fraction in the sweep gas to ~11–14% to avoid hyperoxia. Hemoglobin targets and transfusions were also managed accordingly: early runs needed ~40 mL·kg^–1·week^–1 of blood, but after adjusting cannulation and giving EPO, transfusions dropped to ~6 mL·kg^–1·week^–1. These details underscore the fine feedback needed: O₂ saturation, CO₂, pH, and hematocrit all influence pump settings. Future closed-loop control systems will likely use online sensors and microfluidic regulators to maintain these within fetal norms. Human fetuses are larger and would require more fluid and larger membranes. For example, a 24-week human fetus weighs roughly 500 g and has blood flow ~150 mL·kg^–1·min^–1, so an oxygenator must handle on the order of 75–100 mL/min of blood flow. That implies hundreds of milliliters of fluid and tens of square centimeters of membrane. Engineers must ensure that the bag volume and heat exchanger capacity scale up accordingly, all while maintaining sterility and easy bedside handling. Fluid turnover rates might approach liters per day, and warming/stirring systems must prevent any thermal gradients. Designing a human‑sized Biobag is an ongoing challenge. A clinical artificial womb will require robust monitoring of fetal vitals and system parameters. As one expert noted, fetal monitoring tools have lagged; we now have only ultrasound heart-rate checks. Emerging micro-sensor technologies, like the Northwestern fetal probe, hint at what’s needed: “By tracking multiple vital signs simultaneously, surgeons gain a more complete picture… even as the uterus and fetus moved”. Such hair-thin probes can measure heartbeat, oxygen saturation and temperature in real time. In future artificial gestators, similar soft robotic sensors and cameras will need to relay continuous data on fetal cardiac output, blood gases and fluid chemistry. This data will feed algorithms that adjust pumps, heaters, and gas mixes to keep the fetus in its “comfort zone.”Alongside engineering, ethical and regulatory issues loom large. Artificial wombs blur lines between fetus and patient, creating unprecedented scenarios for human development. As ethicist Elizabeth Romanis, “this kind of device would create a new stage of human development – something we’ve never had to describe or regulate before.” Clinical trials for artificial gestation will require navigating complex consent and safety rules. In fact, the USFDA already convened an expert panel in 2023 to discuss first-in-human trials for extremely preterm infants using extra-uterine life support. The panel noted that in the US, “more than 10,000 infants are born each year” in this extremely preterm window, with traditional care mortality rates over 50%. The promise of extending even 4–6 more weeks of uterine maturation is enormous, but trials must proceed with caution. When it comes to synthetic embryo models, the regulations are changing as well. In fact, the current ISSCR guidelines suggest culturing human embryo-like structures for fourteen days after conception, as this would not lead to the development of a potential sentient embryo. However, as blastoids and gastruloids become more complex, similar regulations need to be considered. In fact, synthetic embryos are being used by engineers for drug testing and research, which is not considered to pose any ethical dilemma in the near future. However, the topic is bound to spark debate in the public sphere. Artificial wombs and synthetic embryos are at the crossroads of stem cell biology and biomedical engineering. Engineers are using their knowledge of fluid mechanics and materials science to reproduce the unique environment of the womb. Successes in lamb experiments—weeks of support with normal growth and development—prove that this is a viable concept. Improvements in oxygenation systems and fluid and sensor systems will be essential to advancing this technology to support human babies. With this technology and proper ethics, this will be a new revolution in neonatal care. In fact, it can prove to be a complete paradigm shift in the treatment of premature babies—saving thousands of lives and preventing disabilities in some of the smallest and most vulnerable patients.Srishti started out as an editor for academic journal articles before switching to reportage. With a keen interest in all things science, Srishti is particularly drawn to beats covering medicine, sustainable architecture, gene studies, and bioengineering. When she isn't elbows-deep in research for her next feature, Srishti enjoys reading contemporary fiction and chasing after her cats.Interviews
Biobag System Biomedical Engineering Ex Utero Gestation Fetal Monitoring Neonatal Technology Organogenesis Stem Cell Engineering Synthetic Embryology Tissue Engineering
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Beijing (CN) job with Zhongguancun Academy - Zhongguancun Institute of Artificial IntelligenceWe are seeking Assistant Professor in Artificial Intelligence and related interdisciplinary fields. We seek innovators with a sharp vision for frontier dynamics, capable of aligning personal research with institutional strategy to establish academic leadership and drive pioneering studies.
Read more »
Beijing (CN) job with Zhongguancun Academy - Zhongguancun Institute of Artificial IntelligenceWe are seeking Associate Professor in Artificial Intelligence and related interdisciplinary fields. Applicants must possess a solid theoretical foundation, keep abreast of cutting-edge developments worldwide, and deliver high-impact research outcomes. Prior experience in teaching and student supervision is highly preferred.
Read more »
US book critics honor Nobel laureate and South Korean novelist Han KangThe National Book Critics Circle honored a novel by Nobel laureate Han Kang and Karen Hao’s examination of artificial intelligence and OpenAI at its annual awards on Thursday.
Read more »
Artificial intelligence will see you now: Bots to prescribe mental health drugsToday's Business Headlines: 03/26/26
Read more »
The AI Doc: Exploring the Promises and Perils of Artificial IntelligenceDocumentary director Daniel Roher investigates the potential future of artificial intelligence, interviewing AI proponents and critics to understand its impact on society. The film aims to demystify AI for a mainstream audience, exploring both its utopian possibilities and potential dangers, ultimately adopting an 'apocaloptimist' perspective.
Read more »
AI’s arrival complicates Big Tech climate goals, and some worry it’s locking in more fossil fuelsThe artificial intelligence race is complicating tech companies’ commitments to reduce greenhouse gas emissions.
Read more »